BRPI1009287A2 - composto de quinoxalina - Google Patents
composto de quinoxalinaInfo
- Publication number
- BRPI1009287A2 BRPI1009287A2 BRPI1009287A BRPI1009287A BRPI1009287A2 BR PI1009287 A2 BRPI1009287 A2 BR PI1009287A2 BR PI1009287 A BRPI1009287 A BR PI1009287A BR PI1009287 A BRPI1009287 A BR PI1009287A BR PI1009287 A2 BRPI1009287 A2 BR PI1009287A2
- Authority
- BR
- Brazil
- Prior art keywords
- quinoxaline compound
- quinoxaline
- compound
- Prior art date
Links
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 title 1
- -1 quinoxaline compound Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009052577 | 2009-03-05 | ||
| PCT/JP2010/053586 WO2010101230A1 (ja) | 2009-03-05 | 2010-03-04 | キノキサリン化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1009287A2 true BRPI1009287A2 (pt) | 2019-09-24 |
Family
ID=42709784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1009287A BRPI1009287A2 (pt) | 2009-03-05 | 2010-03-04 | composto de quinoxalina |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8357688B2 (pt) |
| EP (1) | EP2404922B1 (pt) |
| JP (1) | JP5609861B2 (pt) |
| KR (1) | KR20110132559A (pt) |
| CN (1) | CN102341399A (pt) |
| AU (1) | AU2010219598A1 (pt) |
| BR (1) | BRPI1009287A2 (pt) |
| CA (1) | CA2754457A1 (pt) |
| ES (1) | ES2612954T3 (pt) |
| IL (1) | IL214918A0 (pt) |
| MX (1) | MX2011009314A (pt) |
| PL (1) | PL2404922T3 (pt) |
| PT (1) | PT2404922T (pt) |
| RU (1) | RU2011140333A (pt) |
| TW (1) | TW201043632A (pt) |
| WO (1) | WO2010101230A1 (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110132559A (ko) * | 2009-03-05 | 2011-12-08 | 아스텔라스세이야쿠 가부시키가이샤 | 퀴녹살린 화합물 |
| WO2011028947A2 (en) | 2009-09-03 | 2011-03-10 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| EA201390354A1 (ru) * | 2010-09-07 | 2013-08-30 | Астеллас Фарма Инк. | Хиноксалиновое соединение |
| KR101567610B1 (ko) | 2010-11-04 | 2015-11-09 | 주식회사 엘지화학 | 신규한 질소 함유 헤테로환 화합물 및 이를 이용한 유기 전자 소자 |
| BR112013022147A2 (pt) * | 2011-03-02 | 2017-04-25 | Bioenergenix | composto, composição farmacêutica, método de inibição da pask, método de tratamento de uma doença, método para alcançar um efeito em um paciente e método de tratamento de uma doença mediada pela pask |
| BR112013033375B1 (pt) | 2011-06-27 | 2022-05-10 | Janssen Pharmaceutica N.V | Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário |
| BR112014007912B1 (pt) * | 2011-10-07 | 2022-06-07 | Eisai R&D Management Co., Ltd | Derivados de pirazoloquinolina |
| JP6117334B2 (ja) | 2012-03-23 | 2017-04-19 | メモリアル スローン−ケタリング キャンサー センター | 膵臓癌および関連するがんの５−アシル−６，７−ジヒドロチエノ［３，２−ｃ］ピリジンでの処置 |
| ES2855575T3 (es) | 2012-06-26 | 2021-09-23 | Janssen Pharmaceutica Nv | Combinaciones que comprenden compuestos de 4-metil-[1,2,4]triazolo[4,3-a]quinoxalina como inhibidores de PDE2 e inhibidores de PDE10 para su uso en el tratamiento de trastornos neurológicos o metabólicos |
| MX359843B (es) * | 2013-04-05 | 2018-10-12 | Eisai R&D Man Co Ltd | Sal de derivado de pirazoloquinolina y cristal de la misma. |
| RU2655172C2 (ru) | 2013-04-05 | 2018-05-24 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Пиридинилпиразолохинолиновые соединения |
| US11311530B2 (en) | 2017-06-01 | 2022-04-26 | Eisai R&D Management Co., Ltd. | Lewy body disease therapeutic agent containing pyrazoloquinoline derivative |
| CA3060030A1 (en) | 2017-06-01 | 2018-12-06 | Eisai R&D Management Co., Ltd. | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil |
| AU2018276568A1 (en) | 2017-06-01 | 2019-11-07 | Eisai R&D Management Co., Ltd. | Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine |
| US11484502B2 (en) | 2017-06-01 | 2022-11-01 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition comprising PDE9 inhibitor |
| CN114560862A (zh) * | 2022-03-08 | 2022-05-31 | 山东龙辰药业有限公司 | 一种吡咯并[1,2-a]喹喔啉-4(5h)-酮及其衍生物的合成方法 |
| IL320626A (en) * | 2022-11-10 | 2025-07-01 | Haihe Biopharma Co Ltd | Fused tricyclic parp1 inhibitor, method of preparation thereof, and use thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4035893A (en) | 1991-12-17 | 1993-07-19 | Upjohn Company, The | 3-substituted imidazo (1,5-a) and imidazo (1,5-a)-triazolo (1,5-c) quinoxalines and quinazolines with cns activity |
| JPH07503970A (ja) | 1992-02-19 | 1995-04-27 | ジ・アップジョン・カンパニー | ＣＮＳ活性を有する３−置換イミダゾ（１，５−ａ）−キノキサリン類およびキナゾリン類 |
| DK31093D0 (pt) * | 1993-03-19 | 1993-03-19 | Novo Nordisk As | |
| CA2200055A1 (en) | 1994-09-16 | 1996-03-21 | Novo Nordisk A/S | [1,2,4]triazolo[4,3-a]quinoxalinone derivatives, their preparation and use |
| DE69511420T2 (de) | 1994-09-16 | 2000-03-30 | Novo Nordisk A/S, Bagsvaerd | [1,2,4]-TRIAZOLO[4,3-a]CHINOXALINON-DERIVATE, IHRE HERSTELLUNG UND VERWENDUNG |
| US6235740B1 (en) | 1997-08-25 | 2001-05-22 | Bristol-Myers Squibb Co. | Imidazoquinoxaline protein tyrosine kinase inhibitors |
| HN2002000317A (es) * | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
| US20030195205A1 (en) * | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
| EP1613629A1 (en) | 2003-03-27 | 2006-01-11 | Pfizer Products Inc. | Substituted 4-amino 1,2,4 triazolo 4,3-a quinoxalines |
| ES2526701T3 (es) * | 2005-06-14 | 2015-01-14 | Aska Pharmaceutical Co., Ltd. | Derivado de tienopirimidina |
| CA2659967C (en) | 2006-08-08 | 2014-05-13 | Aska Pharmaceutical Co., Ltd. | Quinazoline derivatives |
| WO2008072779A1 (ja) * | 2006-12-13 | 2008-06-19 | Aska Pharmaceutical Co., Ltd. | キノキサリン誘導体 |
| US20100113484A1 (en) | 2006-12-13 | 2010-05-06 | Aska Pharmaceutical Co., Ltd. | Treating agent of uropathy |
| KR20110132559A (ko) * | 2009-03-05 | 2011-12-08 | 아스텔라스세이야쿠 가부시키가이샤 | 퀴녹살린 화합물 |
-
2010
- 2010-03-04 KR KR1020117020668A patent/KR20110132559A/ko not_active Withdrawn
- 2010-03-04 WO PCT/JP2010/053586 patent/WO2010101230A1/ja not_active Ceased
- 2010-03-04 AU AU2010219598A patent/AU2010219598A1/en not_active Abandoned
- 2010-03-04 MX MX2011009314A patent/MX2011009314A/es not_active Application Discontinuation
- 2010-03-04 PL PL10748823T patent/PL2404922T3/pl unknown
- 2010-03-04 CA CA2754457A patent/CA2754457A1/en not_active Abandoned
- 2010-03-04 CN CN2010800107121A patent/CN102341399A/zh active Pending
- 2010-03-04 PT PT107488231T patent/PT2404922T/pt unknown
- 2010-03-04 EP EP10748823.1A patent/EP2404922B1/en active Active
- 2010-03-04 ES ES10748823.1T patent/ES2612954T3/es active Active
- 2010-03-04 JP JP2011502811A patent/JP5609861B2/ja not_active Expired - Fee Related
- 2010-03-04 RU RU2011140333/04A patent/RU2011140333A/ru not_active Application Discontinuation
- 2010-03-04 BR BRPI1009287A patent/BRPI1009287A2/pt not_active IP Right Cessation
- 2010-03-04 US US13/254,368 patent/US8357688B2/en not_active Expired - Fee Related
- 2010-03-05 TW TW099106457A patent/TW201043632A/zh unknown
-
2011
- 2011-09-01 IL IL214918A patent/IL214918A0/en unknown
-
2012
- 2012-11-27 US US13/686,581 patent/US8674096B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US8357688B2 (en) | 2013-01-22 |
| EP2404922B1 (en) | 2016-11-09 |
| CA2754457A1 (en) | 2010-09-10 |
| ES2612954T3 (es) | 2017-05-19 |
| US8674096B2 (en) | 2014-03-18 |
| EP2404922A1 (en) | 2012-01-11 |
| CN102341399A (zh) | 2012-02-01 |
| EP2404922A4 (en) | 2013-07-03 |
| US20110319385A1 (en) | 2011-12-29 |
| US20130085134A1 (en) | 2013-04-04 |
| RU2011140333A (ru) | 2013-04-10 |
| AU2010219598A1 (en) | 2011-09-22 |
| JPWO2010101230A1 (ja) | 2012-09-10 |
| TW201043632A (en) | 2010-12-16 |
| KR20110132559A (ko) | 2011-12-08 |
| PT2404922T (pt) | 2016-12-22 |
| WO2010101230A1 (ja) | 2010-09-10 |
| MX2011009314A (es) | 2011-10-11 |
| IL214918A0 (en) | 2011-11-30 |
| PL2404922T3 (pl) | 2017-03-31 |
| JP5609861B2 (ja) | 2014-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2017026I1 (el) | Τετρακυκλικη ενωση | |
| BRPI1009287A2 (pt) | composto de quinoxalina | |
| SMT201600008B (it) | Composti di piridazinone | |
| DK2427449T3 (da) | Vinylindazolylforbindelser | |
| BR112012006859A2 (pt) | compostos | |
| BRPI1013614A2 (pt) | compostos substituídos de espiro-amida | |
| BRPI1006760A2 (pt) | montagem | |
| BRPI1013868A2 (pt) | composto diaciletilenodiamina | |
| PT2506716T (pt) | Novos compostos tricíclicos | |
| BRPI1005525A2 (pt) | compostos de azaazuleno | |
| BRPI1008774A2 (pt) | espiroamida substituída | |
| DE112010002949A5 (de) | Kupplungstastpunkte | |
| BRPI1008827A2 (pt) | deisobutenizador | |
| PT2626350E (pt) | Composto de ciclopropano | |
| BRPI1014968A2 (pt) | subalargador | |
| UY33156A (es) | Nuevos compuestos tienopirrol | |
| DE112010002728A5 (de) | Turboinhalator | |
| BRPI1013493A2 (pt) | composto de pirimidina | |
| DE112009005323A5 (de) | Hebelarmprüfmaschine | |
| DE112009005462T8 (de) | Lenkungsssteuervorrichtung | |
| BRPI1008070A2 (pt) | tricianoboratos | |
| BR112012004964A2 (pt) | girocóptero | |
| FR2947857B1 (fr) | Agencement de deshuileur | |
| BRPI0911393A2 (pt) | composto de 5-hidroxipirimidina-4-carboxamida | |
| DE102010023851A8 (de) | Kommutator |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |